Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Marcus M. Schittenhelm, Sharon Shiraga, Arin Schroeder, Amie S. Corbin, Diana Griffith, Francis Y. Lee, Carsten Bokemeyer, Michael W.N. Deininger, Brian J. Druker, Michael C. Heinrich
Dive into the research topics of 'Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies'. Together they form a unique fingerprint.